From the Guidelines
Trimbow should be used twice daily, with each inhalation delivering a fixed combination of 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate, and 9 micrograms of glycopyrronium, providing a total daily dose of 348 micrograms beclometasone, 20 micrograms formoterol, and 36 micrograms glycopyrronium. The standard dose is two inhalations twice daily (morning and evening). Patients should rinse their mouth after each use to reduce the risk of oral thrush. Trimbow is a maintenance therapy for adults with moderate to severe chronic obstructive pulmonary disease (COPD) or inadequately controlled asthma, and should not be used as a rescue medication for acute symptoms. The medication works through three mechanisms: beclometasone reduces airway inflammation, formoterol relaxes airway muscles for bronchodilation, and glycopyrronium blocks muscarinic receptors to prevent airway constriction.
Key Considerations
- Patients should use the inhaler at approximately the same times each day for optimal effectiveness and should not abruptly stop treatment as this may worsen respiratory symptoms.
- The LABA/ICS combination, such as Trimbow, may have a modest effect on overall mortality and improves health-related quality of life and reduces the risk of a COPD exacerbation 1.
- The primary adverse effect attributed to the LABA/ICS combination is an increased risk of pneumonia, although this effect may not be present to the same degree with all formulations of a LABA/ICS 1.
Patient Education
- Patients should be educated on inhaler technique and regularly checked to ensure proper use.
- Choosing the right device for a given patient and regularly checking inhaler use are important components of COPD management 1.
- A high proportion of patients with COPD have poor inhaler technique, which appears to negatively affect outcomes 1.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Recommended Use Frequency and Dose of Trimbow
The recommended use frequency and dose of Trimbow (Glipbohm, Formoterol, Beclomethasone) are not explicitly stated in the provided studies. However, the following information can be gathered:
- Trimbow is a single-inhaler triple therapy that combines an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) 2.
- The extrafine fixed-dose combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide has been developed as a hydrofluoroalkane pressurized metered dose inhaler 3.
- The dose of the extrafine fixed combination is 100 µg/puff of beclomethasone dipropionate, 6 µg/puff of formoterol fumarate, and 12.5 µg/puff of glycopyrronium bromide 3.
- The studies provided do not mention the specific use frequency of Trimbow, but they do discuss the efficacy and safety of the triple combination therapy in patients with chronic obstructive pulmonary disease (COPD) 2, 3, 4, 5, 6.
- The TRITRIAL study protocol mentions that patients will receive therapy with BDP/FF/G (Trimbow) according to the Summary of Product Characteristics and local clinical practice, but it does not specify the use frequency 5.
Key Findings
- The extrafine triple combination therapy has been shown to improve lung function, symptoms, and health status, and reduce exacerbations in patients with COPD 2, 3, 6.
- The therapy has been compared to other pharmacological agents and combinations, and has been found to be effective in delaying disease deterioration 6.
- The studies provided do not discuss the recommended use frequency and dose of Trimbow in detail, but they do provide information on the efficacy and safety of the triple combination therapy in patients with COPD.
Study Limitations
- The studies provided do not explicitly state the recommended use frequency and dose of Trimbow.
- The studies focus on the efficacy and safety of the triple combination therapy in patients with COPD, rather than providing detailed information on the use frequency and dose of Trimbow.